Agios Pharmaceuticals

Agios Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agios Pharmaceuticals excels in Q4, eyes hematology franchise expansion

Agios Pharmaceuticals showcased strong performance and progress in its Q4 2022 earnings call, emphasizing advancements in its pipeline and commercial capabilities. While facing challenges in estimating sales and patient enrollment progression, the company is well-positioned to capitalize on opportunities for growth and expansion.

Agios Pharmaceuticals reports robust Q1 earnings and strategic growth outlook

Agios Pharmaceuticals demonstrated strong financial performance, progress in PK activation therapies, and strategic decision-making in Q1 2023.
While facing challenges in distribution and inventory management, the company's focus on persistency, clear milestones, and launch dynamics present growth opportunities.
Overall, Agios Pharmaceuticals is well-positioned to capitalize on its strengths, address challenges, and leverage opportunities for future success.

Agios Pharmaceuticals reports strong Q2 performance and eyes growth opportunities

Agios Pharmaceuticals shows strong financial performance and pipeline progress.
Challenges include slow uptake for PYRUKYND and clinical development queries.
Exciting opportunities lie in potential acquisitions, peak sales targets, and upcoming data readouts.

Agios Pharmaceuticals excels in Q3, poised for growth and innovation

Agios Pharmaceuticals delivered a strong performance in Q3 2023, achieving key milestones and reporting solid financial results, positioning the company for future growth.
With a focus on pipeline advancements, commercial success, and financial stability, Agios demonstrates resilience and potential in the competitive pharmaceutical landscape.
While facing challenges in competitive markets and the need for further clarity on certain aspects, Agios has opportunities to capitalize on its strengths and drive innovation and growth.

Agios Pharmaceuticals reports robust earnings and eyes market expansion

Agios Pharmaceuticals showcased strong performance in PK activator development, with positive data readouts and financial stability driving growth prospects.
While facing challenges in market differentiation and regulatory approval, the company's strategic strengths in rare disease treatments and operational efficiency position it for long-term success.
With upcoming launches for thalassemia and sickle cell disease, Agios has opportunities to expand its market presence, drive revenue growth, and establish itself as a key player in rare disease therapeutics.

Agios Pharmaceuticals excels in Q1, eyes strong growth opportunities

Agios Pharmaceuticals showcased strong performance with positive clinical data and solid financials.
While facing challenges in market dynamics and cost management, the company is optimistic about future opportunities.
With a focus on partnerships and revenue growth, Agios aims to deliver value to shareholders.
The company's robust pipeline and cash position position it well for future success.

Agios Pharmaceuticals reports robust Q3 performance and eyes future launches

Agios Pharmaceuticals showcased strong financial performance and progress in key therapeutic areas during their Q3 2024 earnings call. While facing challenges in addressing analyst inquiries and market comparisons, the company remains optimistic about their future prospects. Leveraging their strengths in market engagement and scientific innovation, Agios is well-positioned for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

The FDA confers an orphan drug status on Agios' (AGIO) pyruvate kinase-R activator mitapivat for addressing sickle cell disease. Stock climbs in after-hours trading.

Agios' (AGIO) Mitapivat Gets Orphan Drug Tag to Treat SCD

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's first-in-class pyruvate kinase R (PKR) activator mitapivat for the treatment of patients with sickle cell disease. Mitapivat is an investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated PKR enzymes.

Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease

Agios' (AGIO) earnings and revenues fall shy of estimates in the third quarter. The company lifts the lower end of 2020 sales guidance for its leukemia drug Tibsovo.

Agios' (AGIO) Q3 Loss Wider Than Expected, Revenues Miss

Agios Pharmaceuticals' (AGIO) CEO Jackie Fouse on Q3 2020 Results - Earnings Call Transcript

  Shares of Agios Pharmaceuticals (NASDAQ:AGIO) were unchanged after the company reported Q3 results.

Agios Pharmaceuticals: Q3 Earnings Insights

– Third Quarter TIBSOVO® Net Revenue of $31.7 Million; Company Narrows 2020 TIBSOVO® Net U.S. Revenue Guidance to $113–115 Million –

Agios Reports Business Highlights and Third Quarter 2020 Financial Results

Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET Company to Host Virtual Investor Event and Webcast on Tuesday, December 8, 2020 at 8:00 a.m. ET

Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting

CAMBRIDGE, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a webinar focused on its pyruvate kinase-R (PKR) activation clinical programs and the commercial outlook across three distinct hemolytic anemias on Thursday, November 19, 2020 from 8:00 a.m. to 10:30 a.m. ET.

Agios to Host a Webinar on its Pyruvate Kinase-R (PKR) Activation Clinical Programs and Commercial Outlook on Thursday, November 19, 2020

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, November 5, 2020 at 8:00 a.m. ET to report its third quarter 2020 financial results and other business highlights.

Agios to Webcast Conference Call of Third Quarter 2020 Financial Results on November 5, 2020

Agios: A Look At Mitapivat In Anaemia, Its Backup Indication

Agios (AGIO) withdraws the regulatory filing for Tibsovo in Europe, which was developed to treat relapsed/refractory acute myeloid leukemia in adult patients with a susceptible IDH1 mutation.

Agios (AGIO) Withdraws Filing for Leukemia Drug Tibsovo in EU

Agios: A Look At TIBSOVO In CC Patients

– Agios Continues to Advance Two Phase 3 Combination Trials of TIBSOVO ® in Newly Diagnosed AML Patients –

Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO® as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia

Agios Pharmaceuticals (AGIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Agios Pharmaceuticals (AGIO) Rating Upgrade to Buy

–  Supplemental New Drug Application  Planned f or  Submission in Q1 2021  –

Agios Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients

Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020 Andrew Hirsch to Depart Agios and Remain a Strategic Advisor through October 2020  

Agios Appoints Jonathan Biller as Chief Financial Officer, Head of Legal and Corporate Affairs

Tibsovo sales, after weakness during launch, are ramping nicely.

Agios Pharmaceuticals A Buy For Tibsovo, Mitapivat

Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock?

Agios Pharmaceuticals (AGIO) Down 15.5% Since Last Earnings Report: Can It Rebound?

CAMBRIDGE, Mass., Aug.  27, 2020  (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the virtual Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020 at 9:50 a.m. ET.

Agios to Present at the Citi 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020

CAMBRIDGE, Mass., Aug.  06, 2020  (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020 at 1:00 p.m. ET.

Agios to Present at the Virtual Canaccord 40th Annual Growth Conference on Thursday, August 13, 2020

Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q2 2020 Results - Earnings Call Transcript

– Second Quarter TIBSOVO® Net Revenue of $27.6 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million –

Agios Reports Business Highlights and Second Quarter 2020 Financial Results

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Should You Buy?

CAMBRIDGE, Mass., July  16, 2020  (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, July 30, 2020 at 8:00 a.m. ET to report its second quarter 2020 financial results and other business highlights.

News for Agios Pharmaceuticals Stock (AGIO)